This award recognises a European public life science company that has demonstrated a superior excellence in strategy, process, focus and execution to create significant value for patients, investors, employees and the broader life science community.
Judges paid particular attention to:
Using our unique LentiVector® delivery platform, we have created a valuable portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. We have strong partnerships with Novartis, Bioverativ (part of the Sanofi Group), Boehringer Ingelheim, the UK Cystic
Fibrosis Gene Therapy Consortium and Imperial Innovations, Immune Design and Orchard Therapeutics, providing them with access to our intellectual
property, state-of-the-art production facilities and expertise, and, in addition, we have licensed products and technology rights to Boehringer Ingelheim,
Sanofi and Axovant. These partnerships provide us with multiple income streams, consisting of upfront milestone payments, development and production
fees and potential royalties on future product sales. We plan to progress our wholly-owned products via spin-outs and out-licensing opportunities, while continuing to invest in our LentiVector® platform. We plan to continue our preclinical R&D to discover new potential products.